GB9922361D0 - Generating an immune response to an antigen - Google Patents

Generating an immune response to an antigen

Info

Publication number
GB9922361D0
GB9922361D0 GBGB9922361.2A GB9922361A GB9922361D0 GB 9922361 D0 GB9922361 D0 GB 9922361D0 GB 9922361 A GB9922361 A GB 9922361A GB 9922361 D0 GB9922361 D0 GB 9922361D0
Authority
GB
United Kingdom
Prior art keywords
antigen
immune response
epitope
generating
priming composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9922361.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB9922361(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB9922361.2A priority Critical patent/GB9922361D0/en
Publication of GB9922361D0 publication Critical patent/GB9922361D0/en
Priority to CA002384806A priority patent/CA2384806A1/en
Priority to DE60020136T priority patent/DE60020136T2/de
Priority to JP2001524625A priority patent/JP2003509470A/ja
Priority to AU73024/00A priority patent/AU762894B2/en
Priority to DK00960857T priority patent/DK1214416T3/da
Priority to ES00960857T priority patent/ES2241653T3/es
Priority to EP00960857A priority patent/EP1214416B1/en
Priority to PCT/GB2000/003601 priority patent/WO2001021201A2/en
Priority to EP05009308A priority patent/EP1612269A1/en
Priority to AT00960857T priority patent/ATE295421T1/de
Priority to CN00815933A priority patent/CN1391609A/zh
Priority to BR0014138-0A priority patent/BR0014138A/pt
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB9922361.2A 1999-09-21 1999-09-21 Generating an immune response to an antigen Ceased GB9922361D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB9922361.2A GB9922361D0 (en) 1999-09-21 1999-09-21 Generating an immune response to an antigen
BR0014138-0A BR0014138A (pt) 1999-09-21 2000-09-20 Uso de um vetor adenoviral deficiente em replicação, e, métodos para reforçar, e para induzir resposta imune de célula cd8+ t a um antìgeno em um indivìduo
CN00815933A CN1391609A (zh) 1999-09-21 2000-09-20 用复制缺陷腺病毒载体加强cd8+t细胞对抗原的免疫应答
DK00960857T DK1214416T3 (da) 1999-09-21 2000-09-20 Anvendelse af en replikationshæmmet adenoviral vektor til fremstilling af et lægemiddel til stimulering af immunreaktionen mod antigen hos CD+ T-celler
DE60020136T DE60020136T2 (de) 1999-09-21 2000-09-20 Verwendung eines replikationdefizienten adenoviralenvektors zur herstellung eines medikaments zur erhöhung der cd8+ t-zell-immunantwort gegen antigen
JP2001524625A JP2003509470A (ja) 1999-09-21 2000-09-20 抗原に対するｃｄ８＋ｔ細胞免疫応答を増強するための複製欠損性アデノウイルスベクターの使用
AU73024/00A AU762894B2 (en) 1999-09-21 2000-09-20 Use of replication-deficient adenoviral vector to boost CD8+ T cell immune response to antigen
CA002384806A CA2384806A1 (en) 1999-09-21 2000-09-20 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen
ES00960857T ES2241653T3 (es) 1999-09-21 2000-09-20 Utilizacion de un vector adenoviral de replicacion deficiente para la fabricacion de un medicamento destinado a estimular la respuesta inmune de celulas t cd8+ antigeno.
EP00960857A EP1214416B1 (en) 1999-09-21 2000-09-20 Use of replication-deficient adenoviral vector in the manufacture of a medicament to boost cd8+ t cell immune response to antigen
PCT/GB2000/003601 WO2001021201A2 (en) 1999-09-21 2000-09-20 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen
EP05009308A EP1612269A1 (en) 1999-09-21 2000-09-20 Use of replication-deficient adenoviral vector to boost CD8+ T cell immune response to antigen
AT00960857T ATE295421T1 (de) 1999-09-21 2000-09-20 Verwendung eines replikationdefizienten adenoviralenvektors zur herstellung eines medikaments zur erhöhung der cd8+ t-zell- immunantwort gegen antigen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9922361.2A GB9922361D0 (en) 1999-09-21 1999-09-21 Generating an immune response to an antigen

Publications (1)

Publication Number Publication Date
GB9922361D0 true GB9922361D0 (en) 1999-11-24

Family

ID=10861351

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9922361.2A Ceased GB9922361D0 (en) 1999-09-21 1999-09-21 Generating an immune response to an antigen

Country Status (12)

Country Link
EP (2) EP1214416B1 (https=)
JP (1) JP2003509470A (https=)
CN (1) CN1391609A (https=)
AT (1) ATE295421T1 (https=)
AU (1) AU762894B2 (https=)
BR (1) BR0014138A (https=)
CA (1) CA2384806A1 (https=)
DE (1) DE60020136T2 (https=)
DK (1) DK1214416T3 (https=)
ES (1) ES2241653T3 (https=)
GB (1) GB9922361D0 (https=)
WO (1) WO2001021201A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
CA2378539A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
JP4654026B2 (ja) * 2002-05-20 2011-03-16 独立行政法人科学技術振興機構 Ｂｃｇワクチンとその利用
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
AU2003288273A1 (en) 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
CN100410382C (zh) * 2006-08-18 2008-08-13 上海交通大学医学院 一种可诱生细胞免疫应答的共表达载体和真核表达载体
WO2008063555A2 (en) * 2006-11-17 2008-05-29 Genetronics, Inc. Methods of enhancing immune response using electroporation-assisted vaccination and boosting
GB0706912D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
ES2581576T3 (es) * 2007-09-14 2016-09-06 Institut Pasteur Polinucleótidos que permiten la expresión y la secreción de pseudovirus recombinantes que contienen epítopos extraños, su producción y utilización
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
EP2912183B1 (en) * 2012-10-28 2020-05-06 Bavarian Nordic A/S Pr13.5 promoter for robust t-cell and antibody responses
KR20230166145A (ko) 2017-03-15 2023-12-06 옥스포드 바이오메디카(유케이) 리미티드 방법
KR20220082047A (ko) * 2019-10-16 2022-06-16 캔써 리서치 테크놀로지 리미티드 암 치료용 벡터
EP4444347A1 (en) 2021-12-07 2024-10-16 Barinthus Biotherapeutics (UK) Limited Vaccine boost methods and compositions
WO2024218165A1 (en) 2023-04-17 2024-10-24 Barinthus Biotherapeutics (Uk) Limited Hpv viral vector vaccine

Also Published As

Publication number Publication date
CN1391609A (zh) 2003-01-15
JP2003509470A (ja) 2003-03-11
EP1612269A1 (en) 2006-01-04
DE60020136D1 (de) 2005-06-16
AU762894B2 (en) 2003-07-10
EP1214416B1 (en) 2005-05-11
CA2384806A1 (en) 2001-03-29
DE60020136T2 (de) 2006-02-23
EP1214416A2 (en) 2002-06-19
WO2001021201A3 (en) 2001-10-18
ES2241653T3 (es) 2005-11-01
WO2001021201A2 (en) 2001-03-29
DK1214416T3 (da) 2005-08-29
ATE295421T1 (de) 2005-05-15
BR0014138A (pt) 2002-05-21
AU7302400A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
GB9922361D0 (en) Generating an immune response to an antigen
EP1616954A3 (en) Methods and reagents for vaccination which generate a CD8 T cell immune response
AU9435098A (en) Tuberculosis vaccine
DE69734882D1 (de) Dna immunisierung gegen chlamydia infektion
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
GB2384709A (en) Vaccination method
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
DE69229476D1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
WO2001036623A3 (en) Ecdysone-inducible adeno-associated virus expression vectors
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
JP2003509470A5 (https=)
NO983946L (no) Parapoxviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner
WO2000063406A3 (en) Adenoviral vectors having nucleic acids encoding immunomodulatory molecules
CA2327434A1 (en) Dna immunization against chlamydia infection
ATE319833T1 (de) Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
AU3980497A (en) A vector for polynucleotide vaccines
MXPA03010527A (es) Composicion de vacuna.
WO1992014818A3 (en) Entomopoxvirus expression system comprising spheroidin or thymidine-kinase sequences
WO1998015635A3 (en) Treatment of cancer using a recombinant poxvirus containing a nucleic acid sequence encoding a cytokine
WO2002006328A3 (en) Type 2 dendritic cell precursor derived coding nucleic acids and related compositions and methods
HK1083454A1 (en) Recombinant vaccine viruses expressing il-15 and methods of using the same

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)